It has been shown that among UTUC and UCB patients who receive atezolizumab (anti-PD-L1 therapy), the response rate is higher in UTUC than in UCB (39% vs. 17%) 29, 30. Here, CD274 is linked to renal pelvis/ureter urothelial carcinoma.